Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Thymidine Kinase 1 Loss Confers Trifluridine Resistance without Affecting 5-Fluorouracil Metabolism and Cytotoxicity.

Edahiro K, Iimori M, Kobunai T, Morikawa-Ichinose T, Miura D, Kataoka Y, Niimi S, Wakasa T, Saeki H, Oki E, Kitao H, Maehara Y.

Mol Cancer Res. 2018 Jun 4. pii: molcanres.0686.2017. doi: 10.1158/1541-7786.MCR-17-0686. [Epub ahead of print]

PMID:
29866926
2.

A minimal threshold of FANCJ helicase activity is required for its response to replication stress or double-strand break repair.

Bharti SK, Sommers JA, Awate S, Bellani MA, Khan I, Bradley L, King GA, Seol Y, Vidhyasagar V, Wu Y, Abe T, Kobayashi K, Shin-Ya K, Kitao H, Wold MS, Branzei D, Neuman KC, Brosh RM Jr.

Nucleic Acids Res. 2018 Jul 6;46(12):6238-6256. doi: 10.1093/nar/gky403.

PMID:
29788478
3.

Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan.

Liu J, Yasuno S, Oba K, Konda M, Ichihara C, Kitao H, Kuwabara Y, Ueshima K.

J Hypertens. 2018 May 9. doi: 10.1097/HJH.0000000000001780. [Epub ahead of print]

PMID:
29750680
4.

Epithelial Paradox: Clinical Significance of Coexpression of E-cadherin and Vimentin With Regard to Invasion and Metastasis of Breast Cancer.

Yamashita N, Tokunaga E, Iimori M, Inoue Y, Tanaka K, Kitao H, Saeki H, Oki E, Maehara Y.

Clin Breast Cancer. 2018 Feb 16. pii: S1526-8209(17)30629-8. doi: 10.1016/j.clbc.2018.02.002. [Epub ahead of print]

PMID:
29526677
5.

Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.

Inoue Y, Yamashita N, Kitao H, Tanaka K, Saeki H, Oki E, Oda Y, Tokunaga E, Maehara Y.

Clin Breast Cancer. 2017 Nov 21. pii: S1526-8209(17)30385-3. doi: 10.1016/j.clbc.2017.11.008. [Epub ahead of print]

PMID:
29275106
6.

Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication.

Nakanishi R, Kitao H, Kiniwa M, Morodomi Y, Iimori M, Kurashige J, Sugiyama M, Nakashima Y, Saeki H, Oki E, Maehara Y.

Sci Rep. 2017 Dec 5;7(1):16969. doi: 10.1038/s41598-017-17282-5.

7.

Mitotic slippage and the subsequent cell fates after inhibition of Aurora B during tubulin-binding agent-induced mitotic arrest.

Tsuda Y, Iimori M, Nakashima Y, Nakanishi R, Ando K, Ohgaki K, Kitao H, Saeki H, Oki E, Maehara Y.

Sci Rep. 2017 Dec 1;7(1):16762. doi: 10.1038/s41598-017-17002-z.

8.

DNA replication stress and cancer chemotherapy.

Kitao H, Iimori M, Kataoka Y, Wakasa T, Tokunaga E, Saeki H, Oki E, Maehara Y.

Cancer Sci. 2018 Feb;109(2):264-271. doi: 10.1111/cas.13455. Epub 2017 Dec 22. Review.

9.

Activation of the FA pathway mediated by phosphorylation and ubiquitination.

Ishiai M, Sato K, Tomida J, Kitao H, Kurumizaka H, Takata M.

Mutat Res. 2017 Oct;803-805:89-95. doi: 10.1016/j.mrfmmm.2017.05.003. Epub 2017 May 5. Review.

PMID:
28552166
10.

Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women.

Tokunaga E, Yamashita N, Tanaka K, Inoue Y, Akiyoshi S, Saeki H, Oki E, Kitao H, Maehara Y.

PLoS One. 2016 Dec 15;11(12):e0168090. doi: 10.1371/journal.pone.0168090. eCollection 2016.

11.

Prognostic impact of MutT homolog-1 expression on esophageal squamous cell carcinoma.

Akiyama S, Saeki H, Nakashima Y, Iimori M, Kitao H, Oki E, Oda Y, Nakabeppu Y, Kakeji Y, Maehara Y.

Cancer Med. 2017 Jan;6(1):258-266. doi: 10.1002/cam4.979. Epub 2016 Dec 5.

12.

High expression of the Notch ligand Jagged-1 is associated with poor prognosis after surgery for colorectal cancer.

Sugiyama M, Oki E, Nakaji Y, Tsutsumi S, Ono N, Nakanishi R, Sugiyama M, Nakashima Y, Sonoda H, Ohgaki K, Yamashita N, Saeki H, Okano S, Kitao H, Morita M, Oda Y, Maehara Y.

Cancer Sci. 2016 Nov;107(11):1705-1716. doi: 10.1111/cas.13075.

13.

Impact of Expression of Vimentin and Axl in Breast Cancer.

Tanaka K, Tokunaga E, Inoue Y, Yamashita N, Saeki H, Okano S, Kitao H, Oki E, Oda Y, Maehara Y.

Clin Breast Cancer. 2016 Dec;16(6):520-526.e2. doi: 10.1016/j.clbc.2016.06.015. Epub 2016 Jul 5.

PMID:
27506606
14.

[Evolving 5-Fluorouracil Therapy to Achieve Enhanced Efficacy-Past and Current Efforts of Researchers].

Maehara Y, Oki E, Saeki H, Tokunaga E, Kitao H, Iimori M, Niimi S, Kataoka Y, Emi Y, Kakeji Y, Baba H, Shirasaka T.

Gan To Kagaku Ryoho. 2016 Jul;43(7):845-54. Review. Japanese.

PMID:
27431628
15.

Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome.

Ito S, Okano S, Morita M, Saeki H, Tsutsumi S, Tsukihara H, Nakashima Y, Ando K, Imamura Y, Ohgaki K, Oki E, Kitao H, Mimori K, Maehara Y.

Ann Surg Oncol. 2016 Aug;23(Suppl 4):508-515. Epub 2016 Jul 5.

PMID:
27380638
16.

[Oxaliplatin -- A 10-Year Trajectory].

Kanaji S, Oki E, Saeki H, Kitao H, Maehara Y, Kakeji Y.

Gan To Kagaku Ryoho. 2016 Jun;43(6):715-22. Japanese.

PMID:
27306807
17.

[The Molecular Aspect of the Antitumor Effect of Oxaliplatin in Combination with 5-FU].

Kitao H, Kiyonari S, Iimori M, Niimi S, Kataoka Y, Akiyama S, Edahiro K, Nakanishi R, Tokunaga E, Saeki H, Oki E, Kanaji S, Kakeji Y, Maehara Y.

Gan To Kagaku Ryoho. 2016 Jun;43(6):707-14. Japanese.

PMID:
27306806
18.

Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis.

Otsu H, Iimori M, Ando K, Saeki H, Aishima S, Oda Y, Morita M, Matsuo K, Kitao H, Oki E, Maehara Y.

Oncology. 2016;91(1):31-40. doi: 10.1159/000445952. Epub 2016 Jun 2.

PMID:
27245623
19.

The antibodies against 5-bromo-2'-deoxyuridine specifically recognize trifluridine incorporated into DNA.

Kitao H, Morodomi Y, Niimi S, Kiniwa M, Shigeno K, Matsuoka K, Kataoka Y, Iimori M, Tokunaga E, Saeki H, Oki E, Maehara Y.

Sci Rep. 2016 May 3;6:25286. doi: 10.1038/srep25286.

20.

Phosphorylation of EB2 by Aurora B and CDK1 ensures mitotic progression and genome stability.

Iimori M, Watanabe S, Kiyonari S, Matsuoka K, Sakasai R, Saeki H, Oki E, Kitao H, Maehara Y.

Nat Commun. 2016 Mar 31;7:11117. doi: 10.1038/ncomms11117.

21.

[Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)].

Kitao H, Matsuoka K, Iimori M, Tokunaga E, Saeki H, Oki E, Miyamoto Y, Baba H, Maehara Y.

Gan To Kagaku Ryoho. 2016 Jan;43(1):8-14. Review. Japanese.

PMID:
26809521
22.

Intensive Immunofluorescence Staining Methods for Low Expression Protein: Detection of Intestinal Stem Cell Marker LGR5.

Yamazaki M, Kato A, Zaitsu Y, Watanabe T, Iimori M, Funahashi S, Kitao H, Saeki H, Oki E, Suzuki M.

Acta Histochem Cytochem. 2015 Oct 29;48(5):159-64. doi: 10.1267/ahc.15019. Epub 2015 Oct 7.

23.

Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer.

Tokunaga E, Yamashita N, Kitao H, Tanaka K, Taketani K, Inoue Y, Saeki H, Oki E, Oda Y, Maehara Y.

Breast. 2016 Feb;25:62-8. doi: 10.1016/j.breast.2015.10.006. Epub 2015 Nov 11.

PMID:
26577950
24.

The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis.

Kiyonari S, Iimori M, Matsuoka K, Watanabe S, Morikawa-Ichinose T, Miura D, Niimi S, Saeki H, Tokunaga E, Oki E, Morita M, Kadomatsu K, Maehara Y, Kitao H.

Mol Cancer Ther. 2015 Oct;14(10):2332-42. doi: 10.1158/1535-7163.MCT-14-0748. Epub 2015 Jul 24.

25.

Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.

Yamashita N, Tokunaga E, Kitao H, Hitchins M, Inoue Y, Tanaka K, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Oda Y, Saeki H, Oki E, Maehara Y.

Clin Breast Cancer. 2015 Dec;15(6):498-504. doi: 10.1016/j.clbc.2015.06.009. Epub 2015 Jun 18.

PMID:
26195437
26.

Mad2 and BubR1: chemotherapeutic coordinators in gastric cancer.

Iimori M, Kitao H, Maehara Y.

Cell Cycle. 2015;14(7):946. doi: 10.1080/15384101.2015.1018051. No abstract available.

27.

Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks.

Matsuoka K, Iimori M, Niimi S, Tsukihara H, Watanabe S, Kiyonari S, Kiniwa M, Ando K, Tokunaga E, Saeki H, Oki E, Maehara Y, Kitao H.

Mol Cancer Ther. 2015 Apr;14(4):1004-13. doi: 10.1158/1535-7163.MCT-14-0236. Epub 2015 Feb 19.

28.

Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer.

Ando K, Oki E, Saeki H, Yan Z, Tsuda Y, Hidaka G, Kasagi Y, Otsu H, Kawano H, Kitao H, Morita M, Maehara Y.

Cancer Med. 2015 Jan;4(1):75-83. doi: 10.1002/cam4.346. Epub 2014 Oct 30.

29.

Aberrations of BUBR1 and TP53 gene mutually associated with chromosomal instability in human colorectal cancer.

Zhao Y, Ando K, Oki E, Ikawa-Yoshida A, Ida S, Kimura Y, Saeki H, Kitao H, Morita M, Maehara Y.

Anticancer Res. 2014 Oct;34(10):5421-7.

PMID:
25275037
30.

Molecular mechanisms regulating the hormone sensitivity of breast cancer.

Tokunaga E, Hisamatsu Y, Tanaka K, Yamashita N, Saeki H, Oki E, Kitao H, Maehara Y.

Cancer Sci. 2014 Nov;105(11):1377-83. doi: 10.1111/cas.12521. Epub 2014 Oct 29. Review.

31.

Chromosomal instability associated with global DNA hypomethylation is associated with the initiation and progression of esophageal squamous cell carcinoma.

Kawano H, Saeki H, Kitao H, Tsuda Y, Otsu H, Ando K, Ito S, Egashira A, Oki E, Morita M, Oda Y, Maehara Y.

Ann Surg Oncol. 2014 Dec;21 Suppl 4:S696-702. doi: 10.1245/s10434-014-3818-z. Epub 2014 Jun 5.

PMID:
24898425
32.

Contribution of BubR1 to oxidative stress-induced aneuploidy in p53-deficient cells.

Ikawa-Yoshida A, Ando K, Oki E, Saeki H, Kumashiro R, Taketani K, Ida S, Tokunaga E, Kitao H, Morita M, Maehara Y.

Cancer Med. 2013 Aug;2(4):447-56. doi: 10.1002/cam4.101. Epub 2013 Jun 26.

33.

Podoplanin is expressed at the invasive front of esophageal squamous cell carcinomas and is involved in collective cell invasion.

Nakashima Y, Yoshinaga K, Kitao H, Ando K, Kimura Y, Saeki H, Oki E, Morita M, Kakeji Y, Hirahashi M, Oda Y, Maehara Y.

Cancer Sci. 2013 Dec;104(12):1718-25. doi: 10.1111/cas.12286. Epub 2013 Oct 22.

34.

Oxidative DNA damage in human esophageal cancer: clinicopathological analysis of 8-hydroxydeoxyguanosine and its repair enzyme.

Kubo N, Morita M, Nakashima Y, Kitao H, Egashira A, Saeki H, Oki E, Kakeji Y, Oda Y, Maehara Y.

Dis Esophagus. 2014 Apr;27(3):285-93. doi: 10.1111/dote.12107. Epub 2013 Aug 1.

PMID:
23902537
35.

Mortalin is a prognostic factor of gastric cancer with normal p53 function.

Ando K, Oki E, Zhao Y, Ikawa-Yoshida A, Kitao H, Saeki H, Kimura Y, Ida S, Morita M, Kusumoto T, Maehara Y.

Gastric Cancer. 2014 Apr;17(2):255-62. doi: 10.1007/s10120-013-0279-1. Epub 2013 Jul 5.

PMID:
23828548
36.

Involvement of ribonucleotide reductase-M1 in 5-fluorouracil‑induced DNA damage in esophageal cancer cell lines.

Aoki Y, Sakogawa K, Hihara J, Emi M, Hamai Y, Kono K, Shi L, Sun J, Kitao H, Ikura T, Niida H, Nakanishi M, Okada M, Tashiro S.

Int J Oncol. 2013 Jun;42(6):1951-60. doi: 10.3892/ijo.2013.1899. Epub 2013 Apr 16.

PMID:
23588527
37.

Contribution of Aurora-A and -B expression to DNA aneuploidy in gastric cancers.

Honma K, Nakanishi R, Nakanoko T, Ando K, Saeki H, Oki E, Iimori M, Kitao H, Kakeji Y, Maehara Y.

Surg Today. 2014 Mar;44(3):454-61. doi: 10.1007/s00595-013-0581-x. Epub 2013 Apr 10.

PMID:
23572383
38.

Rad9, Rad17, TopBP1 and claspin play essential roles in heat-induced activation of ATR kinase and heat tolerance.

Tuul M, Kitao H, Iimori M, Matsuoka K, Kiyonari S, Saeki H, Oki E, Morita M, Maehara Y.

PLoS One. 2013;8(2):e55361. doi: 10.1371/journal.pone.0055361. Epub 2013 Feb 1.

39.

Vimentin as a poor prognostic factor for triple-negative breast cancer.

Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Aishima S, Morita M, Maehara Y.

J Cancer Res Clin Oncol. 2013 May;139(5):739-46. doi: 10.1007/s00432-013-1376-6. Epub 2013 Jan 26.

PMID:
23354842
40.

PARP and CSB modulate the processing of transcription-mediated DNA strand breaks.

Sakai A, Sakasai R, Kakeji Y, Kitao H, Maehara Y.

Genes Genet Syst. 2012;87(4):265-72.

41.

Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.

Nakanishi R, Harada J, Tuul M, Zhao Y, Ando K, Saeki H, Oki E, Ohga T, Kitao H, Kakeji Y, Maehara Y.

Int J Clin Oncol. 2013 Dec;18(6):1042-8. doi: 10.1007/s10147-012-0501-x. Epub 2012 Nov 29.

PMID:
23188063
42.

CtIP- and ATR-dependent FANCJ phosphorylation in response to DNA strand breaks mediated by DNA replication.

Sakasai R, Sakai A, Iimori M, Kiyonari S, Matsuoka K, Kakeji Y, Kitao H, Maehara Y.

Genes Cells. 2012 Dec;17(12):962-70. doi: 10.1111/gtc.12011. Epub 2012 Nov 15.

43.

Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer.

Tokunaga E, Nakashima Y, Yamashita N, Hisamatsu Y, Okada S, Akiyoshi S, Aishima S, Kitao H, Morita M, Maehara Y.

Breast Cancer. 2014 May;21(3):341-9. doi: 10.1007/s12282-012-0398-2. Epub 2012 Aug 18.

PMID:
22903204
44.

Histone chaperone activity of Fanconi anemia proteins, FANCD2 and FANCI, is required for DNA crosslink repair.

Sato K, Ishiai M, Toda K, Furukoshi S, Osakabe A, Tachiwana H, Takizawa Y, Kagawa W, Kitao H, Dohmae N, Obuse C, Kimura H, Takata M, Kurumizaka H.

EMBO J. 2012 Aug 29;31(17):3524-36. doi: 10.1038/emboj.2012.197. Epub 2012 Jul 24.

45.

The Q motif of Fanconi anemia group J protein (FANCJ) DNA helicase regulates its dimerization, DNA binding, and DNA repair function.

Wu Y, Sommers JA, Loiland JA, Kitao H, Kuper J, Kisker C, Brosh RM Jr.

J Biol Chem. 2012 Jun 22;287(26):21699-716. doi: 10.1074/jbc.M112.351338. Epub 2012 May 10.

46.

FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.

Nakanishi R, Kitao H, Fujinaka Y, Yamashita N, Iimori M, Tokunaga E, Yamashita N, Morita M, Kakeji Y, Maehara Y.

Ann Surg Oncol. 2012 Oct;19(11):3627-35. doi: 10.1245/s10434-012-2349-8. Epub 2012 Apr 12.

PMID:
22526901
47.

ATR-Chk1 signaling pathway and homologous recombinational repair protect cells from 5-fluorouracil cytotoxicity.

Fujinaka Y, Matsuoka K, Iimori M, Tuul M, Sakasai R, Yoshinaga K, Saeki H, Morita M, Kakeji Y, Gillespie DA, Yamamoto K, Takata M, Kitao H, Maehara Y.

DNA Repair (Amst). 2012 Mar 1;11(3):247-58. doi: 10.1016/j.dnarep.2011.11.005. Epub 2011 Dec 20.

PMID:
22188649
48.

Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.

Okada S, Tokunaga E, Kitao H, Akiyoshi S, Yamashita N, Saeki H, Oki E, Morita M, Kakeji Y, Maehara Y.

Ann Surg Oncol. 2012 May;19(5):1499-507. doi: 10.1245/s10434-011-2166-5. Epub 2011 Dec 17.

PMID:
22179631
49.

Evaluation of homologous recombinational repair in chicken B lymphoma cell line, DT40.

Kitao H, Hirano S, Takata M.

Methods Mol Biol. 2011;745:293-309. doi: 10.1007/978-1-61779-129-1_17.

PMID:
21660701
50.

FancJ/Brip1 helicase protects against genomic losses and gains in vertebrate cells.

Kitao H, Nanda I, Sugino RP, Kinomura A, Yamazoe M, Arakawa H, Schmid M, Innan H, Hiom K, Takata M.

Genes Cells. 2011 Jun;16(6):714-27. doi: 10.1111/j.1365-2443.2011.01523.x.

Supplemental Content

Support Center